Biocon and Aurobindo Pharma are identified as facing significant EPS impacts within the generics and biosimilars domain.

As global demand for next-generation therapies on diabetes and weight loss surges, Indian pharmaceutical companies are ...

Cipla Ltd ( ($IN:CIPLA) ) just unveiled an update. Cipla Ltd announced the opening of a special window for the re-lodgement of transfer requests ...

Following the earnings announcement, several brokerage firms revised their target price for the stock, with some estimates ...

Cipla share price gain 3% after Q1 earnings beat estimates, with strong margins, India growth, and positive analyst sentiment ...

Welcome to the Cipla Stock Liveblog, your go-to platform for real-time updates and analysis on a top-performing stock. Stay ...

Cipla consolidated net profit for the quarter ending June 2025 at ₹1291.61 crore was up 10% compared to ₹1175.46 crore in the ...

Cipla is scheduled to announce its April-June quarter earnings for the financial year 2025-26 (Q1FY26) on Friday, July 25, ...

Cipla posted a 10.3% rise in Q1 profit with stable EBITDA margins and strong gross margin expansion helping offset pressure ...

As Cipla turns 90, the pharmaceutical giant is reimagining itself as a brand fit for a wellness-driven, digital-first India.

Aurobindo, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir. Aurobindo, Cipla and ...

India's Cipla (CIPL.NS) said on Saturday that its manufacturing of the COVID-19 remdesivir drug was beginning to catch up with demand after the company sought to boost production amid a massive ...